Difference between revisions of "Rasburicase (Elitek)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
m |
||
| Line 24: | Line 24: | ||
[[Category:FDA approved in 2002]] | [[Category:FDA approved in 2002]] | ||
| + | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 13:34, 22 August 2022
General information
Class/mechanism: Recombinant urate-oxidase. Rasburicase catalyzes the enzymatic oxidation of poorly soluble uric acid into allantoin, an inactive and more soluble metabolite.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Brief patient counseling information can be found in the Rasburicase (Elitek) package insert[1]
History of changes in FDA indication
- 7/12/2002: FDA approved "for initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid."[1]
Also known as
- Brand names: Elitek, Fasturtec, Rasbelon, Rasburnat, Rasby